IntroductionMultiple myeloma (MM) almost exclusively develops in the bone marrow and generates devastating bone destruction by osteoclasts (OCs) recruited around MM cells. A marked stimulation of osteoclastic bone resorption causes debilitating clinical symptoms, including intractable bone pain, disabling multiple fractures, and hypercalcemia. The severity of bone disease correlates with the tumor burden and is one of the major parameters in widely used Durie and Salmon clinical staging system. It is of note that the aggressive features of MM bone lesions have significantly contributed to its poor prognosis despite the recent development of intensive chemotherapeutic regimens. 1,2 Therefore, elucidation of the molecular mechanism of bone destruction and tumor progression is essential for the development of effective therapies to improve survival as well as quality of life of patients with MM.Interactions between receptor activator of nuclear factorkappaB (RANK) expressed on the surface of the OC lineage cells and RANK ligand expressed on stromal cells play a key role in the development and activation of OCs, whereas osteoprotegerin, a decoy receptor for RANK ligand secreted from stromal cells, inhibits RANK ligand-RANK signaling. 3-8 MM cells stimulate osteoclastogenesis by triggering a coordinated increase in RANK ligand and decrease in osteoprotegerin in bone marrow (BM) stromal cells. [9][10][11] We and others have demonstrated that osteoclastogenic CC chemokines macrophage inflammatory protein 1␣ (MIP-1␣) and MIP-1␤ are secreted from most of MM cells and play a critical role in the development of MM bone lesions. [12][13][14][15][16][17][18] These chemokines act on MM cells in an autocrine/paracrine fashion and enhance MM cell adhesion to stromal cells through activation of integrins, including very late antigen-4 (VLA-4). The interaction between MM and stromal cells then induces RANK ligand expression by stromal cells, leading to OC differentiation and activation. 12 Almost exclusive development of MM in the BM suggests that the BM microenvironment supports MM cell growth and survival. Among cell components in the BM, roles of stromal cells in MM cell growth and survival have been extensively studied. When cocultured with MM cells, stromal cells are stimulated to produce interleukin 6 (IL-6), which promotes proliferation of MM cells and prevents them from apoptosis induced by anticancer agents. [19][20][21] Other than stromal cells, OCs induced by MM cells are among major cellular components of the BM microenvironment. Administration of inhibitors of osteoclast activity, including bisphosphonates, RANK-Fc, and osteoprotegerin, not only prevented MMinduced bone destruction but also interfered with tumor progression in animal models of MM. 9,22-25 Repeated administration of bisphosphonates has also been reported to reduce the tumor burden without chemotherapy in a portion of patients with MM. 26 These observations raise a possibility that an interaction between OCs and MM Materials and methods ChemicalsThe f...

A novel 90-kDa protein named periostin, which is preferentially expressed in the periosteum and the periodontal ligament (PDL), may play a role in bone metabolism and remodeling. However, the precise role of periostin in the PDL remains unclear. Therefore, we examined the expression of periostin mRNA during experimental tooth movement. Experimental tooth movement was achieved in 7-week-old male Sprague-Dawley rats. In control specimens without tooth movement, the expression of periostin mRNA was uniformly observed in the PDL surrounding the mesial and distal roots of the upper molars and was weak in the PDL of the root furcation area. The periostin mRNA-expressing cells were mainly fibroblastic cells in the PDL and osteoblastic cells on the alveolar bone surfaces. The divergent expression of periostin mRNA in the PDL began to be observed at 3 h and continued up to 96 h after tooth movement. The maximum changes, which showed stronger staining in the pressure sites than in the tension sites, were observed at 24 h. The expression of periostin mRNA in the PDL 168 h after tooth movement exhibited a similar distribution to that of the control specimens. These results suggest that periostin is one of the local contributing factors in bone and periodontal tissue remodeling following mechanical stress during experimental tooth movement.

Purpose: Receptor activator of nuclear factor-nB ligand (RANKL) is a key mediator of osteoclastogenesis. Because certain types of tumor cells aberrantly express RANKL, and because bone destruction also develops in B-cell lymphomas of bone origin, we investigated RANKL expression and the mechanisms of osteoclastogenesis in B-lymphoid neoplasms. Experimental Design and Results: Immunohistochemistry of bone specimens resected from patients with primary B-cell lymphoma of bone with bone destruction revealed that lymphoma cells express RANKL as well as vascular endothelial cell growth factor (VEGF). The tumor cells isolated from the bone specimens enhanced osteoclastogenesis in vitro. In contrast, B-cell lymphoma infiltrating to the bone marrow without bone destruction did not express RANKL. Both RANKL and VEGF were expressed by a portion of B-lymphoid cell lines, including Daudi and IM-9. These RANKL-expressing tumor cells enhanced osteoclastogenesis from RAW264.7 cells and human monocyte-derived preosteoclasts in the absence of stromal cells/osteoblasts in a RANKL-dependent manner. Furthermore, conditioned media from Daudi cells enhanced transmigration of preosteoclasts that was inhibited by anti-VEGF antibody, suggesting that tumor cell^derived VEGF mediates recruitment of osteoclast precursors. Moreover, cocultures of B-lymphoid cell lines with osteoclasts enhanced the growth of B-lymphoid cells. Conclusions: Some malignant B cells aberrantly express functional RANKL as well as VEGF to enhance osteoclastogenesis. The coexpression of RANKL and VEGF may also contribute to the close cellular interactions with osteoclastic cells, thereby forming a vicious cycle between osteoclastic bone destruction and tumor expansion in bone.Certain types of B-lymphoid neoplasms, such as lymphoma of bone origin and multiple myeloma, exclusively develop and expand in the skeleton. These tumors cause lytic bone lesions, which lead to the debilitating clinical symptoms including intractable bone pain and disabling fractures. In those destructive bone lesions, osteoclasts seem to surround tumor cells and actively resorb bone. Several bone-resorbing factors, including parathyroid hormone -related protein (1), interleukin (IL)-1h (2 -4), and IL-6 (3 -5), have been implicated as causative factors for bone destruction in multiple myeloma, and recent reports including those from ourselves indicate that a C-C chemokine, macrophage inflammatory protein-1a and macrophage inflammatory protein-1h, plays an important role in the development of lytic bone lesions by multiple myeloma (6 -10). However, the pathogenesis as well as the mechanism of bone destruction by B-cell lymphoma of bone origin is largely unknown.Binding of receptor activator of nuclear factor-nB ligand (RANKL; refs. 11 -13) to its receptor (RANK; ref. 14) is essential for the enhancement of osteoclast differentiation, activation, and survival, whereas its decoy receptor, osteoprotegerin (15), inhibits RANKL-RANK signaling. Along with RANKL, macrophage colony-stimulating f...